Results 131 to 140 of about 39,119 (216)

Mycobacterium decipiens Infection in Patient Receiving Anti-TNF-α Therapy, France, 2024. [PDF]

Emerg Infect Dis
Destoop JC, Poignon C, Danjou W, Bleibtreu A, Pourcher V, Monsel G.   +5 more
europepmc   +1 more source

In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin. [PDF]

J Antimicrob Chemother
Chua TP, Huaman JL, Danielewski J, Bradshaw CS, Machalek DA, McDonald MJ, Garland SM, Murray GL.   +7 more
europepmc   +1 more source

Safety and outcome of bedaquiline and delamanid-based longer oral regimen in Indian children less than 5 years with drug-resistant tuberculosis. [PDF]

Lung India
Shah I, Ansari R, Gandhi DN, Jain S, Puri V, Shah D, Mattoo SK, Bodhanwala M.   +7 more
europepmc   +1 more source

Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

Pharmacogenomics (London), 2018
A. Naidoo, V. Ramsuran, M. Chirehwa, P. Denti, H. McIlleron, K. Naidoo, N. Yende-Zuma, Ravesh Singh, S. Ngcapu, M. Chaudhry, M. Pepper, N. Padayatchi   +11 more
semanticscholar   +1 more source

Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies. [PDF]

J Clin Tuberc Other Mycobact Dis
Timboe K, Jackson JB, Becker GL.
europepmc   +1 more source

Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study

Journal of Antimicrobial Chemotherapy, 2018
M. Heinrichs, S. Vashakidze, Ketino Nikolaishvili, Irina Sabulua, N. Tukvadze, N. Bablishvili, Shota Gogishvili, Brent P Little, Adam Bernheim, J. Guarner, C. Peloquin, Henry M. Blumberg, H. Derendorf, R. Kempker   +13 more
semanticscholar   +1 more source

Optimal accompanying diagnosis design through external validation of population pharmacokinetic models for moxifloxacin in tuberculosis patients. [PDF]

BMC Infect Dis
Lee H, Jung W, Chang MJ, Lee S, Chae JW, Savic RM, Yun HY.   +6 more
europepmc   +1 more source

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

Journal of Antimicrobial Chemotherapy, 2017
T. Maitre, G. Petitjean, A. Chauffour, C. Bernard, N. El Helali, V. Jarlier, F. Reibel, P. Chavanet, A. Aubry, N. Veziris   +9 more
semanticscholar   +1 more source

Rifapentine- and moxifloxacin-containing short-course regimens for mild spinal tuberculosis: study protocol for a multicenter, randomized, non-inferiority phase II clinical trial. [PDF]

Front Pharmacol
Wu YE, Cao J, Wang L, Wei YJ, Liu HX, Qi L, Zhang W, Liu F, Zhu ZJ, Fan XT, Wang S, Chen C, Liu XZ, Li Y, Sun ZZ, Pan JB, Yang CQ, Van Den Anker J, Zhang Q, Zhao W.   +19 more
europepmc   +1 more source

Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.−11187G>A Polymorphism in Adults with Pulmonary Tuberculosis

Antimicrobial Agents and Chemotherapy, 2018
M. Weiner, J. Gelfond, T. Johnson-Pais, M. Engle, C. Peloquin, John L. Johnson, Erin E. Sizemore, W. M. Mac Kenzie   +7 more
semanticscholar   +1 more source